HMGCR and migraine disorder: Bi Y et al. (71) found that 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) inhibition, corresponding to the reduction in LDL-C, was significantly causally associated with a lower risk of migraine (OR = 0.73, 95% CI: 0.60–0.89, p = 0.0016).